BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) and cannabis use are each associated with specific cognitive deficits. Few studies have investigated the neurocognitive profile of individuals with both an ADHD history and regular cannabis use. The greatest cognitive impairment is expected among ADHD Cannabis Users compared to those with ADHD-only, Cannabis use-only, or neither. METHODS: Young adults (24.2 ± 1.2 years) with a childhood ADHD diagnosis who did (n=42) and did not (n=45) report past year ≥ monthly cannabis use were compared on neuropsychological measures to a local normative comparison group (LNCG) who did (n=20) and did not (n=21) report past year regular cannabis use. Age, gender, IQ, socioeconomic status, and past year alcohol and smoking were statistical covariates. RESULTS: The ADHD group performed worse than LNCG on verbal memory, processing speed, cognitive interference, decision-making, working memory, and response inhibition. No significant effects for cannabis use emerged. Interactions between ADHD and cannabis were non-significant. Exploratory analyses revealed that individuals who began using cannabis regularly before age 16 (n=27) may have poorer executive functioning (i.e., decision-making, working memory, and response inhibition), than users who began later (n=32); replication is warranted with a larger sample. CONCLUSIONS: A childhood diagnosis of ADHD, but not cannabis use in adulthood, was associated with executive dysfunction. Earlier initiation of cannabis use may be linked to poor cognitive outcomes and a significantly greater proportion of the ADHD group began using cannabis before age 16. Regular cannabis use starting after age 16 may not be sufficient to aggravate longstanding cognitive deficits characteristic of ADHD.
BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) and cannabis use are each associated with specific cognitive deficits. Few studies have investigated the neurocognitive profile of individuals with both an ADHD history and regular cannabis use. The greatest cognitive impairment is expected among ADHD Cannabis Users compared to those with ADHD-only, Cannabis use-only, or neither. METHODS: Young adults (24.2 ± 1.2 years) with a childhood ADHD diagnosis who did (n=42) and did not (n=45) report past year ≥ monthly cannabis use were compared on neuropsychological measures to a local normative comparison group (LNCG) who did (n=20) and did not (n=21) report past year regular cannabis use. Age, gender, IQ, socioeconomic status, and past year alcohol and smoking were statistical covariates. RESULTS: The ADHD group performed worse than LNCG on verbal memory, processing speed, cognitive interference, decision-making, working memory, and response inhibition. No significant effects for cannabis use emerged. Interactions between ADHD and cannabis were non-significant. Exploratory analyses revealed that individuals who began using cannabis regularly before age 16 (n=27) may have poorer executive functioning (i.e., decision-making, working memory, and response inhibition), than users who began later (n=32); replication is warranted with a larger sample. CONCLUSIONS: A childhood diagnosis of ADHD, but not cannabis use in adulthood, was associated with executive dysfunction. Earlier initiation of cannabis use may be linked to poor cognitive outcomes and a significantly greater proportion of the ADHD group began using cannabis before age 16. Regular cannabis use starting after age 16 may not be sufficient to aggravate longstanding cognitive deficits characteristic of ADHD.
Authors: Harrison G Pope; Amanda J Gruber; James I Hudson; Geoffrey Cohane; Marilyn A Huestis; Deborah Yurgelun-Todd Journal: Drug Alcohol Depend Date: 2003-04-01 Impact factor: 4.492
Authors: Peter M Monti; Robert Miranda; Kimberly Nixon; Kenneth J Sher; H Scott Swartzwelder; Susan F Tapert; Aaron White; Fulton T Crews Journal: Alcohol Clin Exp Res Date: 2005-02 Impact factor: 3.455
Authors: Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-02-08 Impact factor: 8.829
Authors: Gene-Jack Wang; Nora D Volkow; Timothy Wigal; Scott H Kollins; Jeffrey H Newcorn; Frank Telang; Jean Logan; Millard Jayne; Christopher T Wong; Hao Han; Joanna S Fowler; Wei Zhu; James M Swanson Journal: PLoS One Date: 2013-05-15 Impact factor: 3.240
Authors: Olivier J Barthelemy; Mark A Richardson; Timothy C Heeren; Clara A Chen; Jane M Liebschutz; Leah S Forman; Howard J Cabral; Deborah A Frank; Ruth Rose-Jacobs Journal: J Stud Alcohol Drugs Date: 2019-01 Impact factor: 2.582
Authors: Natalie Castellanos-Ryan; Jean-Baptiste Pingault; Sophie Parent; Frank Vitaro; Richard E Tremblay; Jean R Séguin Journal: Dev Psychopathol Date: 2016-12-29
Authors: Jerod Rasmussen; B J Casey; Theo G M van Erp; Leanne Tamm; Jeffery N Epstein; Claudia Buss; James M Bjork; Brooke S G Molina; Katerina Velanova; Daniel H Mathalon; Leah Somerville; James M Swanson; Tim Wigal; L Eugene Arnold; Steven G Potkin Journal: Brain Imaging Behav Date: 2016-09 Impact factor: 3.978
Authors: Jenessa S Price; Tim McQueeny; Skyler Shollenbarger; Erin L Browning; Jon Wieser; Krista M Lisdahl Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530
Authors: Krista M Lisdahl; Leanne Tamm; Jeffery N Epstein; Terry Jernigan; Brooke S G Molina; Stephen P Hinshaw; James M Swanson; Erik Newman; Clare Kelly; James M Bjork Journal: Drug Alcohol Depend Date: 2016-02-06 Impact factor: 4.492
Authors: Krista M Lisdahl; Natasha E Wright; Christopher Kirchner-Medina; Kristin E Maple; Skyler Shollenbarger Journal: Curr Addict Rep Date: 2014-06-01